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Abstract
Ovarian cancer is the seventh most common cancer diagnosed in women worldwide. To date, many studies in 
epithelial ovarian cancer (EOC) have reported on the association HER-2/neu, p53 proteins and steroid hormones and 
their respective receptors with prognosis and/or the carcinogenesis process, but no definitive conclusion has been 
reached.
Objectives: To assess the proteins c-erbB-2, p53, Ki67 and receptors of estrogen (ER) and progesterone (PR) of EOC, 
with regard to clinical stage findings and its effect on survival.
Methods: 125 patients with a diagnosis of EOC treated by primary surgery and chemotherapy have participated. 
A surgical stage was noted and analyzed the correlation with c-erbB-2, p53, Ki67, ER and PR. Immunohistochemical 
analysis, using the anti-c-erbB-2, p53, Ki67 monoclonal antibodies, the antibody cod PR clone PgR and code ER-6-F11 
Anti human estrogen. The c-erbB-2 study was complemented by genetic amplification and was reported univariate 
and multivariate analysis.
Results: Age 55.7 ± 16; 50.2% with residual disease (< 2 cm); initial (54.6%) and advanced (45.4%) stage. Univariate 
analysis showed positive staining for c-erbB-2, p-53, Ki67, PR and ER. The patients with negative receptors had a 
significantly shortened survival time (p = 0.01) than patients with positive receptors. Multivariable analysis revealed 
only clinical FIGO stage as an independent prognostic of overall survival (p = 0.002). Other variables like c-erbB-2, p53, 
Ki67, and ER were not significantly related to survival.
Conclusions: We concluded that patients with negative PR had a significantly shortened survival time than patients 
with positive receptors. The overexpression of markers c-erbB-2, p53, Ki67, and ER, were not significantly related to 
survival in EOC. Only the FIGO stage was achieved to be an independent predictor of overall survival. They should be 
evaluated together with the patient’s clinical status and other prognostic factors.
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Introduction
Ovarian cancer is the seventh most common cancer 
diagnosed in women worldwide [1]. Approximately one-
fourth of all gynecologic malignancies are of ovarian 
origin, and 47% of all gynecologic cancer-related deaths 
are due to ovarian cancer. Ovarian cancer carries the 
highest mortality among all gynecological malignancies. 
The high mortality is due mostly to the fact that the 
tumor is frequently diagnosed late, in advanced stages 
(III, or even IV), because the early stages are often 
asymptomatic, and no effective screening methods are 
available [2]. The average 5-year survival of patients in 
all stages of the disease is only 40%, in patients with the 
advanced disease only 10-20% [3]. Some studies reported 
a decreasing incidence in women, attributed to the use of 
an oral contraceptive pill [4,5]. 
It seems that there has been no significant decrease in 
incidence or mortality from ovarian cancer since the early 
1980s, although the imagiologic exams had permitted 
diagnosed more and more the disease in early stages. In 
the absence of preventable etiologic factors or effective 
tools for screening, the only possible means of improving 
survival currently lies with the optimal management of 
patients after initial diagnosis. The prognosis of epithelial 
ovarian cancer can be correlated with biological (age), 
social (performance status) and clinical factors (tumor 
stage, histological grade, histological type, presence or 
absence of ascites; size and number of residual lesions 
after primary cytoreduction surgery, and chemotherapy) 
[6-8]. Identification of new prognostic factors might 
be useful in directing the therapy and intensifying the 
follow-up of a selected group of patients. A variety 
of prognostic factors have been reported, but their 
independent prognostic significance remains unclear. 
Immunohistochemistry has been widely used in the 
biomarkers search.
The oncoprotein c-erbB-2 (HER-2/neu; Neu), encodes 
a transmembrane glycoprotein that is member of the 
class I receptor tyrosine kinase family, which includes 
the epidermal growth factor, HER-2/neu, HER-3 and 
HER-4 [9]. Proto-oncogene HER-2/neu is located on 
chromosome 17 and is not activated by a point mutation 
but through amplification and overexpression of the wild-
type gene. Amplification of the HER-2/neu oncogene may 
be observed in 20-30% of cases in a wide spectrum of 
neoplastic disorders (e.g., breast, lung carcinomas, others), 
and HER-2/neu overexpression has been associated with 
a poor prognosis of patients with cancer arising from 
other primary sites, but studies of ovarian cancer have 
produced conflicting results [10-12]. Patients with breast 
carcinomas with amplified or overexpressed HER-2/neu 
can benefit from anthracycline-based regimens as well 
as Trastuzumab (Herceptin), a recombinant humanized 
monoclonal antibody against the Her-2/neu protein 
[13-15]. HER-2/neu is generally assessed as protein 
overexpression by using immunohistochemistry (IHC), 
and patients with tumors that either have 2+ or 3+ results 
with this method become good candidates for treatment 
with Trastuzumab.
However, studies indicate that HER-2/neu determined 
as gene amplification provides better prognostic 
information and is associated with a better response to 
Trastuzumab. HER-2/neu gene amplification is primarily 
detected by in situ hybridization and uses fluorescence 
(FISH) to detect the signals [16]. This method is expensive, 
it requires a fluorescence microscope, appropriate filters, 
and a sophisticated camera; so it is not practical as a 
screening tool. Chromogenic in situ hybridization (CISH) is 
a recently introduced method, and although it makes use 
of the in situ hybridization technology of FISH, it also takes 
advantage of the chromogenic signal detection of IHC 
that can be detected with the ordinary light microscope 
and has fewer costs [17,18]. CISH is potentially able to 
detect HER-2/neu gene amplification and to minimize, 
if not eliminate, the false positive fraction with the IHC 
procedure.
To date, many studies in epithelial ovarian cancer 
have reported on the association between HER-2/
neu expression and outcome; some earlier studies 
reported that HER-2/neu overexpression was a poor 
prognostic factor, but later studies reported that HER-
2/neu expression had no relationship with prognosis. 
Thus, no definitive conclusion has been reached as to 
the relationship between HER-2/neu expression and 
prognosis [14,19]. Just like of studies in breast also 
for the ovary, more studies should be conducted for 
studies in order to enhance the HER2 prognostic value 
and advantage therapy with monoclonal antibodies 
(Trastuzumab or other) [9,20].
P53 is a tumor suppressor gene (inhibit cell division 
and/or promote cell death/apoptosis) located on the 
short arm of chromosome17 [21]. It suppresses cell 
growth by controlling entry into the S-phase of the cell 
cycle. Mutation or deletion of the p53 gene is believed 
to result in uncontrolled cell proliferation. Most p53 
gene mutations result in stabilization of the protein. In 
contrast to the short half-life of the wild type p53 protein, 
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increased the stability of the mutant forms allows 
their detection by immunohistochemical techniques. 
Mutations of the p53 gene are the most common genetic 
abnormalities described in human cancers and have 
been implicated in the pathogenesis of several human 
tumors [22]. Mutations of the p53 have been found in 
approximately 40-80% of epithelial ovarian cancer cases. 
Studies have demonstrated an association between p53 
protein overexpression and poor prognosis in patients 
with several tumor types. In epithelial ovarian carcinoma, 
the role of p53 protein is contentious, and there are a 
number of studies with contradictory results [23]. There 
are several studies that identified the p53 protein as 
an adverse prognostic factor for survival in ovarian 
cancer; others studies suggested that alterations in p53 
expression in ovarian cancer can to affect the sensibility 
to chemotherapy [24]. In contrast, there are a number 
of studies that suggest that p53 expression has no 
prognostic value in epithelial ovarian cancer [25].
The proliferation activity of the tumor cell can be 
determined using a variety of methods, but many of these 
methods have significant technical limitations (DNA flow 
cytometry, DNA image cytometry, immunohistochemistry 
and others) [26]. Immunohistochemistry allows evaluating 
the Ki67 a nuclear non-histone protein expressed in cells 
in G1, S, G2, and M cell cycle phases, but absenting from 
quiescent cells in G0. High cellular proliferative activity 
was associated with poor outcome. On the other hand, 
other studies did not confirm the relationship between 
proliferation activity and epithelial ovarian cancer 
prognosis [27].
Steroid hormones (estrogen and progesterone) are 
important hormones secreted by the ovary and acting 
through specific receptors. The interaction between 
steroid hormones and their respective receptors 
(estrogen receptor (ER) and progesterone receptor (PR)) 
are thought to play an important role in the process of 
carcinogenesis in gynecologic cancers as well as other 
primary tumors. Since ER and PR were first recognized 
as prognostic factors for breast cancer, much interest 
has been focused on steroid receptors in tumors thought 
to be related to gonadal hormones (endometrium, 
prostatic, ovarian cancer). ER and PR have been found in 
about 50% of ovarian tumors. Although the significance 
of their presence in the pathogenesis of epithelial ovarian 
tumors has not yet been defined [28], a role similar to that 
in breast cancer has been claimed, in that their presence 
seems to be inversely related to tumor differentiation 
but has not yet been confirmed the relationship. Tumor 
expression of ER and/or PR, as well as their pattern of 
combinations (ER+/PR+, ER+/PR-, ER-/PR-), has been 
identified as predictive factors for response to endocrine 
treatment. Some studies found expression of PR to be an 
independent indicator of favorable prognosis in epithelial 
ovarian cancer [29,30]. However, other studies did not 
confirm these results.
Thus, we studied c-erbB-2 (ERBB2, HER-2/neu, neu), 
p53, Ki67 and steroid receptors (ER and PR) tumor 
expression and their possible prognostic value in 
epithelial ovarian cancer.
Objective
The objective was to evaluate the value of proteins 
c-erbB-2, p53, Ki67 and steroids receptors (ER and PR) in 
predicting long-term survival of patients with epithelial 
ovarian cancer.
Material and Methods
This retrospective study comprised one hundred and 
twenty-five patients with an epithelial ovarian cancer 
diagnosis and treated, at the Gynecologic Oncology 
Centre, Hospital Geral Santo Antonio, Porto, Portugal.
All patients were treated by multidisciplinary medical-
surgical teams and by international protocols. All patients 
were staged according to the criteria of the International 
Federation of Gynecology and Obstetrics FIGO) staging 
system I-IV, and after surgery received six courses of 
chemotherapy basis platinum.
In this series, all were invasive tumors. All histological 
sections were reviewed by reference pathologist and 
histological classifications were performed using the 
criteria defined by the World Health Organization (WHO). 
The tumors were graded according to the WHO histologic 
grading system as grade 1, 2 or 3. Clinical information 
was available for all patients (age, date of initial diagnosis, 
surgical stage, histological type, tumor grade, initial 
tumor volume, residual tumor volume, treatment, follow-
up), and the date of death confirmed. 
Immunohistochemical staining
The expression of markers was detected using the 
three-step streptavidin-biotin immunoperoxidase 
method. The monoclonal antibodies to human c-erbB-2 
(1:100, CB11, Zymed), p53 (1:30, D07, Novocastra), Ki67 
(1:20, MM1, Novocastra), ER (1:20, ER-6-F11, Novocastra), 
and PR (1:20, PGR, Novocastra) were used to identify 
the immune staining. Tissue sections from paraffin-
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embedded tissue were deparaffinized in xylene, 
rehydrated through a downgraded alcohol series and 
washed with phosphate-buffered saline (PBS).
To improve antigen detection, the sections were pre-
treated in a microwave oven (900 W) for 20 min in a 
10 mM citrate buffer pH 6.0 or EDTA buffer pH 8.0, for 
the deferent’s markers. After cooling, the sections were 
immersed in 3% hydrogen peroxide (H2O2) and distilled 
water for 30 min to block endogenous peroxidase activity. 
Nonspecific staining was eliminated by 60 min incubation. 
Excess normal serum was removed and replaced by 
primary antibodies used and incubated overnight (4°C) 
in a humidified chamber. After washing the slides, the 
sections were incubated in streptavidin-biotin-complex 
(HRP, Labvision Corporation) for 20 min at room 
temperature. Subsequently, the color was developed with 
3, 3 diaminobenzidine tetrahydrochloride with H2O2 in 
PBS buffer for 5min. Slides were counterstained with Gill’s 
hematoxylin, were dehydrated and mounted. Primary 
antibodies and biotinylated secondary antibodies were 
diluted in PBS. Negative controls were carried out by 
replacing the primary antibody with PBS. Paraffin sections 
from ovarian cancer with known immunoreactivity to 
c-erbB-2, p53, Ki67, ER, and PR antigens were used as 
positive controls. For each case, positively-stained tumor 
cells within five microscopic fields with the highest 
immunoreactivity (“hot spot” areas) were counted at high 
magnification (400x) using a 10×10 grid.
 
For the determination of c-erbB-2 protein 
overexpression, only the membrane staining intensity 
was evaluated. In samples in which CB11 were used as a 
primary antibody, intensity was graded as 0 (staining not 
greater than the negative control), 1+ (light staining - < 
10%), 2+ (moderate staining -10 to 30%), or 3+ (intense 
staining - > 30%). The samples were considered to present 
c-erbB-2 overexpression when staining was intense (3+).
The study of c-erbB-2 was complemented by 
genetic amplification through the chromogenic in 
situ hybridization technique (CISH), with the following 
procedure: tissues 4-5 μm thick were mounted on 
Histogrip-treated microscope slides, dried at 37°C, and 
baked for 2-4 hours at 60°C. The slides were deparaffinized 
for 15 min three times in xylene at room temperature (22-
27°C) and washed for 2 min three times in 100% ethanol 
at room temperature. The slides were microwaved in 
SPOT-Light Tissue Heat Pretreatment Buffer for 10 min 
at 92°C and washed for 3 min twice in PBS. They were 
covered with 100 μL SPOT-Light Tissue Pretreatment 
Enzyme for 10 min at 37°C and washed for 2 min three 
times in PBS at room temperature. The slides were then 
dehydrated in 70%, 85%, 95%, and 100% ethanol for 2 
min each, then air-dried. Denatured probe (15 μL) was 
added to the center of each sample and covered with 
a 24 mm × 32 mm coverslip, the edges of which were 
sealed with a thin layer of rubber cement to prevent the 
evaporation of probe solution during incubation. The 
slides were denatured at 94°C for 3 min and placed in a 
dark humidity box for 16-24 hours at 37°C. After removal 
of the rubber cement and coverslip, the slides were 
immersed in 0.5 × SCC buffer in a Coplin jar for 5 min at 
75°C. They were then washed for 2 min three times in 
PBS-Tween 20 buffer at RT. The slides were submerged 
in peroxidase quenching solution and then washed for 
2 min three times with PBS, after which endogenous 
biotin blocking was performed with Reagent A (100 μL 
of CAS Block). Using Zymed’s SPOT-Light Detection Kit, 
100 μL each of fluorescein isothiocyanate-labeled sheep 
anti-digoxigenin, horseradish peroxidase-labeled goat 
anti-fluorescein isothiocyanate, and diaminobenzidine 
chromogen were sequentially added to the slides, with 
three 2 min rinses with PBS-Tween between the additions 
of reagents. The slides were counterstained with 150 
μL of Gill-2 hematoxylin and incubated for 3 min. They 
were then dehydrated with a graded series of alcohol, 
cleared in xylene, and mounted with a coverslip. The 
results of amplification were recorded as follows: two to 
four signs - lack of amplification; four to six signs - result 
misunderstanding; more than six signs - the presence of 
amplification. In all cases where there was amplified, the 
minimum number of signs was always clearly exceeding 
6. The signs were or clearly distinct from each other or 
confluent, among themselves, in the stain.
Positive staining for p53 was nuclear. The reaction for 
p53 was considered positive when more than 25% of the 
tumors cells exhibited strong diffuse immunostaining. The 
Ki67 labeling index (LI) was calculated as the percentage 
of positive nuclei divided by the total number of cells 
examined. At least 1000 cells per tumor were examined. 
Staining in more than 10% (LI) of the tumor cells was 
considered positive. For the ER and PR, the percentage of 
tumor cells that exhibited nuclear staining for a particular 
receptor regardless of intensity was considered positive 
when more than 10% of cells showed stained.
Statistical analysis
The statistical analysis was done using the SPSS 
statistical package for Windows, version 22 (IBM SPSS, 
Chicago, IL). For univariate analysis, survival time was 
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analyzed by the Kaplan-Meier method, and the log-
rank test was used to assess differences among groups. 
For multivariate analysis, Cox proportional hazard 
regression model was used to examine all factors 
found to be predictive of survival in univariate analysis 
simultaneously. Associations between tested parameters 
were studied by Spearman rank correlation. Differences 
were considered statistically significant at p = 0.20.
Results
The mean age of 86 patients was 55.7 ± 16 years (range 
23-85 years). The median follow-up of patients was 70.5 
months. In this series, the FIGO’s stage I and II were 47 
cases and stage III and IV were 39 cases. Concerning the 
survival rate, the group I and II were grouped and groups 
III and IV as well. Overall survival was defined as the time 
from diagnosis until death or the date of the last follow-
up. 
The immunohistochemical results (N and %) for Ki67, 
p53, PR, and ER are presented in table 1.
The study of HER-2/neu in our series was some 
difficulties arising largely because the older cases have 
had histologic, stages processing more or less time-
consuming Bouin fixing, which is an excellent fixative 
for certain tissues (e.g., for lymphomas), but it has the 
disadvantage of hamper studies immunocytochemistry, 
as occurs with the HER-2/neu. This limitation is felt 
in studies of immunocytochemistry and much more 
obvious becomes when we perform molecular genetic 
studies, such as CISH. Therefore, only 42 cases to obtain 
a material with an acceptable quality of fixing to perform 
immunocytochemistry and CISH. The results are shown 
in table 2, which underline the following data: of the 42 
cases included 7 had intensity of positivity 2; 8 with the 
intensity was 3. In the other, the intensity 1 was 22 cases 
and 0 presented 5 cases.
In all cases, where the intensity of reaction was 0 
or 1, gene amplification was through CISH. In 7 cases 
in which the intensity of positivity was 2, there were 
4 amplification and absence in the other 3. In 8 cases, 
where the intensity was 3, all gene amplification showed 
to CISH. So, the concordance between 3+ IHC and CISH-
amplified cases was 100%, denoting all gene amplified 
cases to be overexpressing the HER-2/neu protein.
The entire cases with gene amplification and thus 
positive, for HER-2/neu, was 12 in 42, that is 28.57% 
of cases. We have not found an association between 
overexpression/amplification (IHC/CISH) and prognosis. 
We noted that IHC/CISH-positive cases, as well as CISH-
positive-only cases, had the same prognosis regarding 
survival, whereas IHC-positive-only cases had a prognosis 
similar to that of IHC/CISH-negative tumors. 







(overall±standard deviation) 23.92 ± 15.71
Median 20







(overall±standard deviation) 62.07 ±  21.84
Median 70







(overall±standard deviation) 38.96 ± 24.75
Median 37.5






(overall±standard deviation) 36.73 ± 22.71
Median 30
Min; Max 10.0; 90.0
Variation Interquart. 42.5
The amplification evidenced by CISH was the second 
two patterns: or present themselves as signals and points 
individually and independently; or existing between 
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themselves, presenting itself as a stain (Figures 1 and 2).
HER 2 - ICQ
2 + 3 +
Figure 1: HER-2/neu - Immunocytochemistry (IHC)-
(400x).
Figure 2: HER-2/neu– Chromogenic in situ hybridization 
(CISH). 
Results for FIGO stage showed that this variable 
correlated significantly with survival (P = 0.002) (Table 3 
and Figure 3).
In univariate analysis, the survival time was longer in 
patients with stage I-II disease than in those with stages 
III-IV disease (Cox p = 0.002). In the first group (I-II) the 
overall survival was 179.7 months (IC = 143.2-216.2) and 
in the second group (III-IV), the overall survival was 73.4 
months (IC = 39.4-107.0).
The univariate analysis did not show an association 
of HER-2/neu protein expression with overall survival. 
Also, in the multivariate analysis the overexpression/
amplification protein was not proven as an independent 
prognostic indicator.
Figure 3: Overall survival of patients with epithelial 
ovarian carcinoma related to the FIGO stage.
The survival in relation to markers HER-2/neu, p53, 
Ki67, and steroids receptors (ER and PR), the univariate 
analysis of clinical follow-up data revealed that patients 
with negative PR, had a significantly shortened survival 
time (p = 0.01) than patients with positive (Table 3 and 
Figure 4).
Figure 4: Overall survivals of patients with epithelial 
ovarian carcinoma relative to progesterone receptor. 
Table 2: HER-2/neu: Immunohistochemistry and CISH. 
Nº of cases HER-2/neu (ICQ) CISH (AMPLIFICATION)
0 1+ 2+ 3+ 0 1+ 2+ 3+ Total
42 5 22 7 8 0 0 4 8 12
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Other variables like HER-2/neu, P53, Ki67 and ER were 
not significantly related to survival (Table 3). 
Table 3: Univariate survival analysis (Kaplan-Meier) 




















In the multivariable statistical analysis only FIGO stage 
(P = 0.002) was achieved to be independent predictor 
of overall survival (Table 4). None of the other variables 
showed any independent predictive value for patient 
prognosis.
In this study, the p53 suppressor gene showed a positive 
percentage (41.6%) and the univariate analysis did not 
show an association of p53 overexpression and prognosis 
(with overall survival) (Table 1). Also, the Multivariate 
analysis not showed that the p53 overexpression protein 
was not proven as an independent prognostic indicator.
Other market studded by immunohistochemical, 
the proliferative market Ki67 (with positive percentage, 
24.0%) did not show association Ki67 expression with 
overall survival by the univariate analysis, as well as in 
multivariate analysis, the Ki67 was not proven as an 
independent prognostic indicator (Table 1).
The percentage of PR positive was 19.2% and ER 
positive 20.0%. We found that PR was associated with 
a better prognosis. Univariate analysis of clinical follow-
up data revealed that patients with negative PR, had 
a significantly shortened survival time (p = 0.01) than 
patients with positive (Table 3 and Figure 4). The same 
was not observed with the ER.
Table 4: Multivariable analysis of survival time using 
cox’s regression proportional hazards model for 
identification of independent prognostic factors for 
patients with ovarian carcinoma.












Wide substantial progress has been made and 
although more and more patients are living longer with 
their disease, the majority of patients with advanced 
ovarian cancer are not cured. The prognosis of ovarian 
cancer is discouraging compared to other malignancies 
of the female genital tract. Despite aggressive surgery 
and intensified chemotherapy, the outcome of patients 
with stage III and IV is poor. The importance of staging 
with regard to survival also stems from the influence it 
has on subsequent patient management. The prognostic 
value of stage according to the FIGO has been well 
established [8]. In a surgical staging procedure, there is 
some controversy over some aspects, especially in the 
early stages (I-II), regarding the status of retroperitoneal 
lymph nodes. When is presumed FIGO I and II stage, the 
extensive surgical staging showed that tumors were a 
more advanced stage, in general stage III. The “aggressive 
surgical staging” cannot significantly change the survival 
of the patients, but it can increase the operation risk 
[3,31]. In our study, unlike the great majority of the series, 
the percentage of early stages (I-II) cancers was higher 
compared to the advanced stage cancers. This is due to 
many of these cases been referred to the hospital. Most 
of the patients were diagnosed in routine gynecologic 
exams or by other specialties after the realization of 
imagiologic exams, for different clinical indications. In 
fact, nowadays, it seems like patients with ovarian cancer 
may be diagnosed at early stages, as a result of better 
primary care by general practitioners. Nevertheless, we 
still diagnose a great number of advanced stage cancers, 
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although this number may be decreasing. 
In this study, only the FIGO stage was achieved to 
be an independent predictor of overall survival by the 
multivariable statistical analysis. None of the other 
variables showed any independent predictive value for 
patient prognosis. The stage is reorganized as the most 
important prognostic factor in epithelial ovarian cancer 
[8,32,33].
Valid prognostic factors are necessary to estimate the 
course of the disease and to define biologically similar 
subgroups for the analysis of therapeutic efficacy [32,34]. 
Many studies have been devoted to finding “Prognostic 
Factors”, and numerous features have been described 
that can help predict the prognosis of early and advanced 
ovarian cancer with varying degrees of accuracy and may 
provide a better understanding of the biological behavior 
of ovarian tumors. Immunohistochemistry has been 
widely used in the search of such marchers [35-37].
The HER-2/neu expression can be determined through 
IHC, FISH, CISH, and ELISA among other tests. This 
oncogene has been studied mainly in breast cancer by 
IHC and FISH where it has a prognostic, predictive and 
therapeutic target value. The HER-2/neu expressionin 
epithelial ovarian cancer has been less studied and we 
studied the overexpression by IHC and the amplification 
by CISH, a promising practical alternative to FISH. After 
the first CISH study by Tanner and colleagues [38] 
other reports favorably validated CISH results and the 
concordance between CISH and FISH [17,39-41]. Some 
reports noted the advantages of CISH over FISH; because 
CISH is a specific, sensitive, and easily applicable method 
for the detection of HER-2/neu gene amplification, and 
it can be used together with IHC for the evaluation of 
patients with breast carcinoma [17,18]. In this study, 
different series reported positivity frequencies of 
overexpression, it may be attributable to the type of 
material analyzed (fresh or embedded in paraffin) and to 
differences in specificity among antibodies used. Enzyme 
and microwave treatment of the tissue during the staining 
process may greatly affect the staining results, and tissue 
fixation procedures may also influence immunostaining. 
Different scoring methods and subjective interpretation 
of immunohistochemical analysis may also be reasons 
for different results obtained by different studies.
In our study, the percentage positive of HER-2/neu 
has not found an association between overexpression/
amplification (IHC/CISH) and it was not proven as an 
independent prognostic indicator. Researchers have 
been trying to assess the real prognostic significance 
of HER-2/neu in ovarian cancer, but the results of their 
studies have been controversial. Some earlier studies 
reported that HER-2/neu overexpression was a poor 
prognostic factor [42,43], but later studies reported that 
HER-2/neu expression had not any relationship with 
prognosis [11,12,44,45]. Thus, no definitive conclusion 
has been reached as to the relationship between HER-2/
neu expression and prognosis.
The same happens with the role of the p53 protein in 
epithelial ovarian cancer, several studies have identified 
the p53 protein as an adverse prognostic factor for 
survival in epithelial ovarian cancer [46]. However, other 
studies suggest that p53 expression has not prognostic 
value in epithelial ovarian cancer [47]. De Graeff and 
collaborators showed in meta-analysis that the outcome 
of analysis was influenced by FIGO stage, for example: 
in some studies the p53 overexpression was associated 
with shorter survival of patients in stage I and II, but 
not in advanced stage III and IV; in other studies, found 
contradictory results, with shorter survival in an advanced 
stage but not in the early stage of the tumors with p53 
overexpression [47]. In our study, we don’t find any 
association of the p53 overexpression with the predictive 
value of overall survival in early stage or advanced stage. 
As for the other markers studied by 
immunohistochemical, we used the proliferative marker 
Ki67 that did not show association Ki67 expression with 
overall survival, as well as the Ki67 was not proven as 
an independent prognostic indicator. Studies on DNA 
content and proliferation in epithelial ovarian cancer 
have contradictory results regarding the prognostic 
significance of these parameters. Authors showed 
that ovarian cancer had a higher median percentage 
of Ki67 staining than borderline and benign tumors, 
and they found a significant relationship between the 
proliferative market Ki67 and disease-free survival that 
was independent the others parameters as histologic 
type, histologic grade, and stage [48]. Others authors also 
observed that Ki67 is a marker that differs in expression 
significantly between the short and long-term survivors 
[14,48]. Poor outcome was associated with the high 
proliferative activity, however series of studies did not 
confirm the relationship between proliferative activity 
and prognosis in epithelial ovarian cancer.
In our study, the percentage of PR was associated with a 
better prognosis, the univariate analysis of clinical follow-
177 Cur Op Gyn Obs, 2(1): 169-179 (2019)  
up data revealed that patients with negative PR, had a 
significantly shortened survival time than patients with 
positive. The same was not observed with ER. Therefore, 
some of the latest studies of the analysis of ER and PR 
status showed that steroids receptors have significant 
favorable prognostic value in ovarian cancer. Especially 
progesterone positive tumor receptor status is proved 
to be an independent prognostic variable of improved 
progression for free-survival among patients with ovarian 
carcinoma. This anti-tumor effect of PR (significant 
survival benefit) may be due to two hypotheses that have 
been proposed. Estrogen-responsive cells efficiently 
repair DNA and avoid apoptosis; progesterone promotes 
cell differentiation and apoptosis, and stimulation of PR 
inhibits DNA synthesis and cell division. What justified 
the theory, proposed to explain the causal mechanism 
of carcinogenesis, the hypothesis “incessant ovulation”, 
that argues that repeated cycles of ovulation-induced 
trauma and repair of the ovarian surface epithelium 
(OSE) at the site of ovulation. According to with this 
hypothesis, the protective effect of progesterone will 
be: decreasing the exposure of the OSE to high levels 
of estrogens; antagonizing the growth-promoting effect 
of estrogens on OSE; inducing the apoptosis of tumor 
cells [49]; loss chromosome 11q23.3-24.3 decreasing 
PR expression and elevated risk for ovarian cancer and 
poorer prognosis. So, this may explain why patients with 
ER + and PR- tumors have the worst and patients with 
ER- and PR+ tumors the best prognosis. It is important 
to identify reliable prognostic markers, such as PR. So, 
maybe possible targets of therapy.
Conclusion
Although this study, with a relatively small number of 
cases, we conclude that patients with negative PR had 
a significantly shortened survival time (p = 0.01) than 
patients with positive. The overexpression of markers 
HER-2/neu, p53, Ki67 and ER, were not significantly 
related to survival in ovarian carcinoma. CISH is a 
promising, practical alternative to FISH that can be used 
in conjunction with IHC, which remains the first screening 
procedure of choice. IHC is easy to perform, relatively 
inexpensive, and able to detect a majority of ovarian 
cancer patients whose tumors have negative (0 or 1+) 
or positive (3+) HER-2/neu status, all three of which have 
complete concordance with CISH.
Only FIGO stage was achieved to be an independent 
predictor of overall survival. They should be evaluated 
together with the patient’s clinical status and other 
prognostic factors.
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